MA49055A - Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf - Google Patents

Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf

Info

Publication number
MA49055A
MA49055A MA049055A MA49055A MA49055A MA 49055 A MA49055 A MA 49055A MA 049055 A MA049055 A MA 049055A MA 49055 A MA49055 A MA 49055A MA 49055 A MA49055 A MA 49055A
Authority
MA
Morocco
Prior art keywords
pentacyclic
modulators
merged
tnf activity
imidazoles
Prior art date
Application number
MA049055A
Other languages
English (en)
Other versions
MA49055B1 (fr
Inventor
Daniel Christopher Brookings
Haro Garcia Teresa De
Yann Foricher
Helen Tracey Horsley
Martin Clive Hutchings
James Andrew Johnson
Malcolm Maccoss
Mengyang Xuan
Zhaoning Zhu
Original Assignee
Sanofi Sa
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58632834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49055(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa, UCB Biopharma SRL filed Critical Sanofi Sa
Publication of MA49055A publication Critical patent/MA49055A/fr
Publication of MA49055B1 publication Critical patent/MA49055B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA49055A 2017-04-25 2018-04-24 Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf MA49055B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17168027 2017-04-25
PCT/EP2018/060489 WO2018197503A1 (fr) 2017-04-25 2018-04-24 Dérivés d'imidazole pentacycliques fusionnés utilisés en tant que modulateurs de l'activité du tnf

Publications (2)

Publication Number Publication Date
MA49055A true MA49055A (fr) 2021-05-05
MA49055B1 MA49055B1 (fr) 2021-12-31

Family

ID=58632834

Family Applications (2)

Application Number Title Priority Date Filing Date
MA49055A MA49055B1 (fr) 2017-04-25 2018-04-24 Dérivés d'imidazoles pentacycliques fusionnés en tant que modulateurs de l'activité de tnf
MA57699A MA57699B1 (fr) 2017-04-25 2018-08-24 Dérivés d'imidazoles pentacycliques condensés en tant que modulateurs de l'activité de tnf

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA57699A MA57699B1 (fr) 2017-04-25 2018-08-24 Dérivés d'imidazoles pentacycliques condensés en tant que modulateurs de l'activité de tnf

Country Status (33)

Country Link
US (4) US10980814B2 (fr)
EP (2) EP3615534B1 (fr)
JP (2) JP7083358B2 (fr)
KR (1) KR102565132B1 (fr)
CN (1) CN110582495B (fr)
AR (1) AR111426A1 (fr)
AU (1) AU2018259040B2 (fr)
CA (1) CA3058980A1 (fr)
CL (1) CL2019002875A1 (fr)
CO (1) CO2019012856A2 (fr)
CR (1) CR20190526A (fr)
DK (1) DK3615534T3 (fr)
EA (1) EA039049B1 (fr)
ES (2) ES2956555T3 (fr)
HR (1) HRP20211927T1 (fr)
HU (1) HUE056593T2 (fr)
IL (1) IL269890B (fr)
LT (1) LT3615534T (fr)
MA (2) MA49055B1 (fr)
MX (1) MX2019012443A (fr)
MY (1) MY197212A (fr)
PE (1) PE20200662A1 (fr)
PH (1) PH12019502182B1 (fr)
PL (2) PL3939980T3 (fr)
PT (2) PT3939980T (fr)
PY (1) PY1829804A (fr)
RS (1) RS62596B1 (fr)
SG (1) SG11201908871SA (fr)
SI (1) SI3615534T1 (fr)
TW (1) TWI801378B (fr)
UY (1) UY37700A (fr)
WO (1) WO2018197503A1 (fr)
ZA (1) ZA201906255B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10766906B2 (en) * 2016-04-01 2020-09-08 UCB Biopharma SRL Fused hexacyclic imidazole derivatives as modulators of TNF activity
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
ES2951837T3 (es) * 2018-10-24 2023-10-25 UCB Biopharma SRL Derivados de imidazol pentacíclicos condensados como moduladores de la actividad de TNF
CN120418259A (zh) 2022-11-23 2025-08-01 弗沃德医疗公司 TNFα活性的调节剂
KR20260004440A (ko) 2023-04-26 2026-01-08 사노피 종양 괴사 인자 알파의 소분자 저해제를 사용한 건선 치료
TW202513567A (zh) * 2023-06-09 2025-04-01 大陸商上海翰森生物醫藥科技有限公司 五環類衍生物抑制劑、其製備方法與應用
IL325727A (en) 2023-07-04 2026-03-01 Sanofi Sa Crystalline form
WO2025038927A1 (fr) 2023-08-16 2025-02-20 Raythera, Inc. Modulateurs de l'activité du tnf alpha et leurs utilisations
IL327415A (en) 2023-09-29 2026-05-01 Sanofi Preparation of bridged pentacyclic imidazole derivatives as modulators of TNF activity, intermediates and their preparation
TW202602881A (zh) * 2024-03-27 2026-01-16 大陸商海思科醫藥集團股份有限公司 雜環衍生物及其在醫藥上的應用
TW202547476A (zh) 2024-04-03 2025-12-16 美商弗沃德醫療公司 TNF-α活性調節劑
TW202604511A (zh) * 2024-04-17 2026-02-01 大陸商上海翰森生物醫藥科技有限公司 五環類衍生物抑制劑、其製備方法與應用
WO2025247401A1 (fr) * 2024-05-31 2025-12-04 海思科医药集团股份有限公司 Dérivé hétérocyclique fusionné et son utilisation pharmaceutique
WO2025252251A1 (fr) * 2024-06-07 2025-12-11 上海翰森生物医药科技有限公司 Inhibiteur de dérivé hétérocyclique contenant de l'oxygène, son procédé de préparation et son utilisation
WO2026012303A1 (fr) * 2024-07-09 2026-01-15 Hangzhou Highlightll Pharmaceutical Co., Ltd NOUVEAUX COMPOSÉS BENZO[4,5]IMIDAZO EN TANT QUE MODULATEURS DE TNFα
WO2026022134A1 (fr) 2024-07-23 2026-01-29 Sanofi Nouveaux procédés d'aminocarbonylation
WO2026021586A1 (fr) * 2024-07-26 2026-01-29 上海瀚辰星泰医药科技有限公司 Composé polycyclique, son procédé de préparation et son utilisation
WO2026027449A1 (fr) 2024-07-29 2026-02-05 Sanofi Dérivés d'imidazole pentacycliques fusionnés
WO2026051930A1 (fr) * 2024-09-04 2026-03-12 苏州湃玥生物科技有限公司 Dérivé de benzimidazole pentacyclique fusionné utilisé en tant que modulateur d'activité de tnf, son procédé de préparation et son utilisation
WO2026055519A1 (fr) 2024-09-06 2026-03-12 Rapt Therapeutics, Inc. Composés imidazole à cycle fusionné
WO2026064602A1 (fr) * 2024-09-23 2026-03-26 Synnovation Therapeutics, Inc. COMPOSÉS HÉTÉROCYCLIQUES EN TANT QUE MODULATEURS DE L'ACTIVITÉ DU TNFα
WO2026068677A1 (fr) 2024-09-27 2026-04-02 Sanofi Procédés de préparation d'imidazoles pentacycliques fusionnés et d'intermédiaires

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2874303C (fr) * 2012-06-11 2020-10-13 Ucb Biopharma Sprl Benzimidazoles modulant l'activite tnf -alpha
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
US9309243B2 (en) * 2012-07-13 2016-04-12 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
PE20170693A1 (es) 2014-10-03 2017-06-13 Ucb Biopharma Sprl Derivados de imidazol pentaciclicos fusionados
UY36630A (es) * 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf

Also Published As

Publication number Publication date
AU2018259040A1 (en) 2019-10-31
JP2022116233A (ja) 2022-08-09
TWI801378B (zh) 2023-05-11
ES2893807T3 (es) 2022-02-10
JP2020517637A (ja) 2020-06-18
CR20190526A (es) 2020-01-07
JP7299382B2 (ja) 2023-06-27
KR102565132B1 (ko) 2023-08-08
WO2018197503A1 (fr) 2018-11-01
UY37700A (es) 2018-11-30
MA57699B1 (fr) 2023-11-30
IL269890B (en) 2022-03-01
PL3939980T3 (pl) 2024-02-05
RS62596B1 (sr) 2021-12-31
AR111426A1 (es) 2019-07-10
US20230250105A1 (en) 2023-08-10
PT3939980T (pt) 2023-08-07
MA49055B1 (fr) 2021-12-31
AU2018259040B2 (en) 2022-04-28
ES2956555T3 (es) 2023-12-22
CL2019002875A1 (es) 2020-03-06
PE20200662A1 (es) 2020-06-11
SI3615534T1 (sl) 2022-01-31
DK3615534T3 (da) 2021-10-18
EP3939980B1 (fr) 2023-07-26
US10980814B2 (en) 2021-04-20
JP7083358B2 (ja) 2022-06-10
PH12019502182A1 (en) 2020-06-08
TW201841918A (zh) 2018-12-01
MX2019012443A (es) 2020-01-13
PH12019502182B1 (en) 2024-01-31
US20200046723A1 (en) 2020-02-13
PY1829804A (es) 2019-03-01
SG11201908871SA (en) 2019-10-30
CA3058980A1 (fr) 2018-11-01
US20210252012A1 (en) 2021-08-19
MY197212A (en) 2023-06-01
EA201992407A1 (ru) 2020-04-06
EP3615534A1 (fr) 2020-03-04
NZ758198A (en) 2024-01-26
KR20190141200A (ko) 2019-12-23
EP3939980A1 (fr) 2022-01-19
HUE056593T2 (hu) 2022-02-28
CO2019012856A2 (es) 2020-01-17
EA039049B1 (ru) 2021-11-26
PT3615534T (pt) 2021-10-21
LT3615534T (lt) 2021-11-25
EP3615534B1 (fr) 2021-09-15
CN110582495A (zh) 2019-12-17
ZA201906255B (en) 2021-01-27
CN110582495B (zh) 2022-04-01
HRP20211927T1 (hr) 2022-03-18
US20250127795A1 (en) 2025-04-24
PL3615534T3 (pl) 2022-01-31
BR112019020314A2 (pt) 2020-04-28

Similar Documents

Publication Publication Date Title
LT3615534T (lt) Sulieti pentacikliniai imidazolo dariniai kaip tnf aktyvumo moduliatoriai
IL283179A (en) Fusosome compositions for cns delivery
EP3442942A4 (fr) Dérivés de bisphénol et leur utilisation en tant que modulateurs de l'activité du récepteur des androgènes
MA40770A (fr) Dérivés d'imidazoles pentacyclic fusionnés
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA49061A (fr) Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
EP3277381C0 (fr) Dérivés de nitrobenzyle d'agents anticancéreux
MA49128A (fr) Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
EP3328379A4 (fr) Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
MA43512A (fr) Composés hétérocycliques utiles en tant que modulateurs du tnf alpha
EP3353328A4 (fr) Modulateurs de l'expression de kras
EP3558237C0 (fr) Système d'application ciblée d'agents topiques à une partie de corps isolée
MA44075A (fr) Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
DK3824731T3 (da) Aortakanyle til ex vivo-organplejesystem
EP3654987A4 (fr) Utilisation de dérivés aminoalkylbenzothiazépine
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
IL266505B (en) Heterocyclic modulators of lipid synthesis
IL262708B (en) Di-substituted pyrazole compounds for the treatment of diseases
MA49017A (fr) Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques
IL241318A0 (en) Bicyclo [2.2.2] acid gpr120 modulators